For example, miR-182 appears protective against glioma based on the TCGA analysis [71, 310]; it targets oncogenes such as c-Met, HIF2A, and Bcl2L12, it sensitized glioma to therapy-induced apoptosis, and its intravenous administration in SNA nanoparticles reduces tumor burden and increases the survival of mice with the orthotopic GBM [310, 311]. The gene discussed is BCL2L12; the disease is central nervous system cancer.